Ackman Says Valeant Is a Problem He Knows How to Handle

  • Hedge fund manager says no widespread investor redemptions
  • 83% of investors able to redeem stayed in fund, Ackman says

Valeant Analyst: More Bad News to Come

Activist investor Bill Ackman said drugmaker Valeant Pharmaceuticals International Inc. is a problem, but one that he knows how to handle.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.